<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101150</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00008644</org_study_id>
    <nct_id>NCT03101150</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D3 Supplementation in Pregnancy on Risk of Pre-eclampsia</brief_title>
  <official_title>Effect of Antenatal Vitamin D3 Supplementation on Risk of Pre-eclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Fahad Medical City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Fahad Medical City</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D deficient pregnant ladies were selected and randomized into 2 groups for routine
      daily dose of multivitamin (400IU vitamin D3) versus maximum safest treatment daily dose
      (4000IU vitamin D3). Participants were assessed and compared for number of pre-eclampsia
      cases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D3 has key role in decidualization and implantation of placenta.Vitamin D deficiency
      is thought to have positive association with pre-eclampsia.Vitamin D deficiency is highly
      prevalent in some parts of the world and it is not universally screened antenatally.
      Pre-eclampsia is a known multifactorial pregnancy disorder with significant maternal and
      perinatal morbidity and mortality. Vitamin D3 has a down-regulating effect on inflammatory
      pathways and reducing endothelial cell damage.

      Investigators want to assess in vitamin D deficient group whether treatment reduces the risk
      of pre-eclampsia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2012</start_date>
  <completion_date type="Actual">December 31, 2015</completion_date>
  <primary_completion_date type="Actual">October 31, 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Pre-eclampsia in Both Arms</measure>
    <time_frame>From 20 weeks of pregnancy till event of pre-eclampsia seen, whichever came first, assessed up to 32 weeks.</time_frame>
    <description>Occurrence of pre-eclampsia or not in all patients irrespective of Vitamin D dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Vitamin D Level</measure>
    <time_frame>At 36th week of pregnancy</time_frame>
    <description>Level of Improvement in Vitamin D status in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Intrauterine Growth Retardation</measure>
    <time_frame>At delivery</time_frame>
    <description>Patients having fetus with retardation of growth in both arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>400 IU Vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400IU vitamin D3 contained in antenatal multivitamin once daily by mouth starting from 14 weeks of pregnancy till delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4000 IU Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4000 IU Vitamin D3 drops once daily by mouth starting from 14 weeks of pregnancy till delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400 IU Vitamin D3</intervention_name>
    <description>Antenatal multivitamin</description>
    <arm_group_label>400 IU Vitamin D3</arm_group_label>
    <other_name>Materna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4000 IU Vitamin D3</intervention_name>
    <description>4000 IU Vitamin D3 (cholecalciferol) daily = 40 drops daily</description>
    <arm_group_label>4000 IU Vitamin D3</arm_group_label>
    <other_name>Vidrop</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed singleton pregnancy of less than 13 completed weeks of gestation at the time
             of consent.

          -  Planned to receive antenatal care in King Fahad Medical City antenatal clinic.

          -  The ability to provide written informed consent at the first visit.

          -  Low risk pregnancy; and Serum vitamin D3 levels less than &lt; 25nmol/L.

        Exclusion Criteria:

          -  Mothers with pregnancy with abnormal foetus.

          -  Previous history of hypertension, pre-eclampsia, recurrent miscarriages.

          -  Chronic kidney disease, chronic liver disease, and malignancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant population</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <results_first_submitted>April 6, 2017</results_first_submitted>
  <results_first_submitted_qc>February 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2018</results_first_posted>
  <last_update_submitted>February 24, 2018</last_update_submitted>
  <last_update_submitted_qc>February 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Fahad Medical City</investigator_affiliation>
    <investigator_full_name>Aisha Mansoor Ali</investigator_full_name>
    <investigator_title>Assistant Consultant Obstetric and Gynecology</investigator_title>
  </responsible_party>
  <keyword>Maternal vitamin D</keyword>
  <keyword>Deficiency</keyword>
  <keyword>Insufficiency</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Pre-eclampsia</keyword>
  <keyword>IUGR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>416 participants were screened. 192 did not meet eligibility criteria. 38 refused to participate and 7 turned out to be ectopic pregnancy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>400 IU</title>
          <description>Materna tablet once daily orally from 14 weeks of pregnancy til delivery.</description>
        </group>
        <group group_id="P2">
          <title>4000 IU</title>
          <description>Vidrop vitamin D 40 drops daily orally from 14 weeks of pregnancy till delivery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscarriage</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>400 IU Vitamin D3</title>
          <description>400IU vitamin D3 contained in antenatal multivitamin once daily by mouth starting from 14 weeks of pregnancy till delivery.
400 IU Vitamin D3: Antenatal multivitamin</description>
        </group>
        <group group_id="B2">
          <title>4000 IU Vitamin D3</title>
          <description>4000 IU Vitamin D3 drops once daily by mouth starting from 14 weeks of pregnancy till delivery.
4000 IU Vitamin D3: 4000 IU Vitamin D3 (cholecalciferol) daily = 40 drops daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="93"/>
            <count group_id="B3" value="179"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" spread="5.3"/>
                    <measurement group_id="B2" value="29.4" spread="4.8"/>
                    <measurement group_id="B3" value="29.3" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Saudi Arabia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="7.3"/>
                    <measurement group_id="B2" value="28.1" spread="7.2"/>
                    <measurement group_id="B3" value="28.4" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primiparity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pre-eclampsia in Both Arms</title>
        <description>Occurrence of pre-eclampsia or not in all patients irrespective of Vitamin D dose.</description>
        <time_frame>From 20 weeks of pregnancy till event of pre-eclampsia seen, whichever came first, assessed up to 32 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>400 IU</title>
            <description>Materna tablet once daily orally from 14 weeks of pregnancy til delivery.</description>
          </group>
          <group group_id="O2">
            <title>4000 IU</title>
            <description>Vidrop vitamin D 40 drops daily orally from 14 weeks of pregnancy till delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pre-eclampsia in Both Arms</title>
          <description>Occurrence of pre-eclampsia or not in all patients irrespective of Vitamin D dose.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Eligible and consented study subjects were randomized according to permuted block design scheme to be allocated in 400 IU arm and 4000 IU arm.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A sample size of minimum 152 was calculated to be able to determine incidence of preeclampsia that is in the range of 8-17% with 80% power assuming an alpha of 5%.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.163</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vitamin D Level</title>
        <description>Level of Improvement in Vitamin D status in both arms</description>
        <time_frame>At 36th week of pregnancy</time_frame>
        <population>Out of 86 participants randomized for the arm of 400 IU, 3 had miscarriage and 2 lost to follow. So 81 participants were analyzed.
Out of 93 participants randomized for the arm of 4000 IU, 6 had miscarriage and 4 lost to follow. So 83 were analyzed in that arm.</population>
        <group_list>
          <group group_id="O1">
            <title>400 IU</title>
            <description>Materna tablet once daily orally from 14 weeks of pregnancy til delivery.</description>
          </group>
          <group group_id="O2">
            <title>4000 IU</title>
            <description>Vidrop vitamin D 40 drops daily orally from 14 weeks of pregnancy till delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vitamin D Level</title>
          <description>Level of Improvement in Vitamin D status in both arms</description>
          <population>Out of 86 participants randomized for the arm of 400 IU, 3 had miscarriage and 2 lost to follow. So 81 participants were analyzed.
Out of 93 participants randomized for the arm of 4000 IU, 6 had miscarriage and 4 lost to follow. So 83 were analyzed in that arm.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" spread="20.7"/>
                    <measurement group_id="O2" value="72.3" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Intrauterine Growth Retardation</title>
        <description>Patients having fetus with retardation of growth in both arms.</description>
        <time_frame>At delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>400 IU</title>
            <description>Materna tablet once daily orally from 14 weeks of pregnancy til delivery.</description>
          </group>
          <group group_id="O2">
            <title>4000 IU</title>
            <description>Vidrop vitamin D 40 drops daily orally from 14 weeks of pregnancy till delivery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Intrauterine Growth Retardation</title>
          <description>Patients having fetus with retardation of growth in both arms.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.02</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>400 IU</title>
          <description>Materna tablet once daily orally from 14 weeks of pregnancy til delivery.</description>
        </group>
        <group group_id="E2">
          <title>4000 IU</title>
          <description>Vidrop vitamin D 40 drops daily orally from 14 weeks of pregnancy till delivery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Consultant Obstetritian and Gynecologist</name_or_title>
      <organization>King Fahd Medical City</organization>
      <phone>00966539417217</phone>
      <email>amali@kfmc.med.sa</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

